TDK <6762>: ¥9,503 (+¥640).
The stock market rebounded significantly. It is reported that a new material for solid state batteries has been developed, which is viewed as a buying opportunity. By using the "electrolyte" which is important for the storage capacity, the energy density of the rechargeable battery is said to be increased 100 times compared to conventional products. It is expected to be installed in small devices such as smart watches and hearing aids and plans to be shipped as samples by 2025. The new material is expected to be an oxide-based material.
YAMAN <6630>: ¥888 (-¥21).
Continued decline. Daiwa Securities has maintained its investment rating of "4" and lowered its target stock price from ¥850 to ¥650 following the announcement of last weekend's financial results. It seems that it will take some time to expand into new domestic areas while the demand in China continues to decline, and the situation is expected to remain weak in the future. The estimated operating profit for the year ending March 2025 is ¥2 billion against the company's plan of ¥2.5 billion and it is expected to be ¥3 billion for the fiscal year ending March 2026.
JESHD <6544>: ¥2,543 (+¥119).
Significant rebound. Tokai Tokyo Securities has newly rated it as "outperform" and set a target stock price of ¥3,400. The growth potential in the medium to long term is expected to be high due to the growth of maintenance and conservation business as well as renewal business. For the year ending in March 2025, it is expected to have an operating profit of ¥88.1 billion against the company's planned ¥8 billion, an increase of 29.2% compared to the previous year. It seems that high valuation can be tolerated due to the shareholder return policy, which stipulates a dividend payout ratio of 40% or more.
Chijyo <3252>: ¥2,547 (+¥257).
Significant rebound. Daiwa Securities has newly rated it as "1" and set a target stock price of ¥3,560. In the future, it is expected that high-profit growth will be recognized due to the reduction in risk premiums and the increase in profits due to the sale and operation of underlying real estate investment trusts (REITs). It seems that there is also a possibility that a large increase in dividends from the next fiscal year will push up the stock price. The expected annual dividend for the year ended December 2024 is ¥85, up ¥30 from the previous year, but Daiwa Securities is forecasting ¥100 for the year ending December 2025 and ¥120 for the year ending December 2026.
FUJITA KANKO <9722>: ¥7,120 (+¥1,000).
At the stop limit. Although no new materials have been observed, it is speculated that the upward revision of performance expectations announced in a quarterly magazine released the day before could be a clue. It seems to be based on factors such as an increase in the occupancy rate due to an increase in the number of visitors to Japan. In addition, this fiscal year marks the first time in five years that dividends will be paid and there is also anticipation for shareholder benefits, such as the provision of discount vouchers to shareholders at the end of June. Some believe the rise in the stock price of DOWAHD, its largest shareholder, and the announcement of the number of foreign visitors to Japan tomorrow may impact on this stock.
Recovery <9214>: ¥1510 (+¥95)
Significantly surged. It announced a share buyback after the end of trading on the 17th. The total number of shares that can be acquired is 70,000 shares (4.95% of the total number of issued shares excluding treasury shares) with a total acquisition price limit of 100 million yen. The acquisition period is from July 1st to November 30th. Its purpose is to improve capital efficiency, enhance shareholder benefits, and enable flexible capital policy in the future.
CarnaBio <4572>: ¥419 (+¥39)
A sharp rise. It is viewed as a positive development that it has presented promising initial data for the Phase 1b clinical trial targeting mature B-cell tumors of the next-generation BTK inhibitor AS-1763 at the European Hematology Association in 2024. Regarding the ongoing Phase 1b trial of AS-1763, promising initial data including tumor reduction effects for mature B-cell tumor patients with many previous treatments were announced in addition to good safety and pharmacokinetic profile results of AS-1763. It is planned to start a dose expansion part based on these promising data within 2024.
CocoPeri <4167>: ¥455 (+¥27).
Sharp rise. It is well received that it has announced the development of "BIG ADVANCE GLOBAL" after the end of trading on the 17th. The current mainstay of small and medium-sized enterprise (SME) DX support platform "Big Advance" is a business matching in Japan only, but it will be able to match with foreign companies. As part of its SME management support, it aims to support SMEs' overseas expansion by connecting Japanese SMEs with overseas companies through partnerships with local financial institutions overseas, despite the difficulty of overseas expansion despite the strong desire of many Japanese SMEs.